We thus propose that treatments that target DDR1–IKKβ–NF-κB–NRF2 signalling and mitochondrial biogenesis should be evaluated in prospective clinical trials that include stromal state—an important modifier of tumour growth—as an integral biomarker. The gene discussed is NFKB1; the disease is neoplasm.